68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors

Neuroendocrine Tumors

Carcinoid Tumors

Neuroblastoma

Medulloblastoma

1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.

68Ga-DOTATOC PET/C

University of Iowa Health Care

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT.

We will 1) compare this unique PET/CT scan with the current standard of care which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those patients who have had recent treatment after the initial PET/CT scan (e.g., surgery, chemotherapy, targeted therapy such as anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), we will measure response to treatment.

IPD are entered into the subject's electronic medical record and are shared with referring physicians when obtained.

Sue O'Dorisio

Professor of Medicine

The Octreoscan and 68Ga-DOTA-tyr3-Octreotide PET scans are read independently by two certified nuclear medicine physicians for discordant positive lesions.

germanium/sarcoma

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

La base de datos de hierbas medicinales más completa respaldada por la ciencia